Overview

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Status:
Not yet recruiting

Trial end date:
2030-12-01

Target enrollment:

Participant gender:

Summary

The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not. The investigators invented a multi-classifier system that was successfully categorise patients with stage III pRCC into high-risk and low-risk groups. Here the investigators randomly assign classifier-defined high risk patients of stage III pRCC into adjuvant pembrolizumab group placebo group. Disease-free survival and overall survival are the end points of observation.

Phase:

Phase 3

Details

Lead Sponsor:

First Affiliated Hospital, Sun Yat-Sen University

Treatments:

Pembrolizumab